Results 81 to 90 of about 3,958 (169)

Immune-Mediated Liver Injury From Checkpoint Inhibitors Requiring Supratherapeutic Corticosteroid and Mycophenolate Treatment

Annals of Internal Medicine: Clinical Cases
A 43-year-old woman with metastatic adrenocortical carcinoma from the left adrenal gland for which she was prescribed therapeutic mitotane was found to have grade 4 immune-mediated liver injury caused by checkpoint inhibitors that was unresponsive to ...
Christopher Pham, Elsie Ennin, Kathryn Enriquez, Alexandra Wong, Sophie M. Cannon, Matthew Dukewich, Jonathan S. LoPresti, Lily Dara, Evanthia T. Roussos Torres   +8 more
doaj   +1 more source

Studio dell’azione del Mitotane, farmaco adrenolitico, sulla funzionalità ipofisaria

, 2011
Mitotane (o,p_-DDD), a derivative of the insecticide dichlorodiphenyltrichloroethane, has been widely used for treatment of adrenocortical carcinoma (ACC).
GENTILIN, Erica
core  

Mitotane and Carney Complex: ten years follow-up of a low-dose mitotane regimen inducing a sustained correction of hypercortisolism. [PDF]

, 2015
OBJECTIVE: Primary pigmented nodular adrenocortical disease (PPNAD), an uncommon cause of Cushing’s syndrome, is frequently associated with a wider clinical spectrum, the Carney complex (CC), a multiple endocrine neoplasia syndrome.
Grilli G., LAMACCHIA, OLGA, CIGNARELLI, MAURO, Picca G., Farese A., Campo M.R., Conserva A.   +6 more
core  

High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up

, 2012
BackgroundThe benefit-to-risk ratio of a high-dose strategy at the initiation of mitotane treatment of adrenocortical carcinoma (ACC) remains unknown.MethodsTo evaluate the performance of a high-dose strategy, defined as the highest tolerated dose ...
Abir Al Ghuzlan, Isabelle Borget, Martin Schlumberger, Desiree Deandreis, Sophie Mauclère-Denost, Angelo Paci, Philippe Chanson, Sophie Leboulleux, Jacques Young, Laurence Drouard, Antoine Tabarin, Eric Baudin   +11 more
core   +1 more source

Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly

, 2008
Toxicity of adjuvant mitotane treatment is poorly known; thus, our aim was to assess prospectively the unwanted effects of adjuvant mitotane treatment and correlate the findings with mitotane concentrations.
Reimondo G, Zaggia B, BERRUTI, Alfredo, Daffara F, Terzolo M., Porpiglia F, Dogliotti L, Volante M, Angeli A, Termine A, Di Carlo F, De Francia S, Aroasio E   +12 more
core  

Issue Information

IJU Case Reports, Volume 8, Issue 5, Page 437-440, September 2025.
wiley   +1 more source

Development of microemulsion of mitotane for improvement of oral bioavailabilty

, 2010
Le mitotane ou o,p'-DDD est un dérivé organochloré très peu soluble dans l'eau. Il est utilisé dans le traitement du cancer corticosurrénalien métastasé ou inopérable (Lysodren®).
Attivi, David
core  

Antineoplastic effect of block-and-replace strategy for managing hypercortisolism caused by adrenal cortical carcinoma. [PDF]

JCEM Case Rep
Bettini DL, Rodella S, Laganà M, Turla A, Berruti A, Cosentini D.   +5 more
europepmc   +1 more source

Evaluation of Curcumin as a Supplement to Improve Mitotane Effects on Adrenocortical Carcinoma. [PDF]

Cells
Nocito MC, Amico A, Hamad T, Cormace A, Hantel C, Morelli C, Sisci D, Lanzino M, Pezzi V, Casaburi I, Sirianni R.   +10 more
europepmc   +1 more source

Enhanced efficiency in mitotane therapeutic drug monitoring: optimization of chromatographic resolution and column longevity. [PDF]

Clinics (Sao Paulo)
Marques ASF, Mendonca BB, Lima-Valassi HP.   +2 more
europepmc   +1 more source